ArticleBioinformatics (Oxford, England)2026
When multimodal fusion fails: contrastive alignment as a necessary stabilizer for TCR-peptide binding prediction.
Article in Bioinformatics (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
motivationMultimodal learning is often assumed to improve predictive performance by combining complementary views, yet in biological applications auxiliary modalities are frequently imperfect, incomplete, or derived from upstream predictors and heuristics. We study this issue in TCR-peptide binding prediction, where sequence embeddings from pretrained protein language models are strong and transferable, but structure-derived residue graphs must be built from predicted folds and discretized contacts. These structural views can therefore be noisy, inconsistent across proteins, and sensitive to modeling choices, making them difficult to optimize jointly with sequence features. In this setting, naive sequence + graph fusion can destabilize training and degrade generalization, falling below a sequence-only baseline when supervision is scarce or contacts are noisy. This motivates a practical goal: use imperfect structural information when it helps, without sacrificing stability when it does not.
resultsWe introduce TRACE, a lightweight framework that encodes each entity (TCR and peptide) with parallel sequence (frozen ESM-2) and residue-graph (GNN) towers, then applies CLIP-style intra-entity contrastive alignment before interaction modeling. The alignment encourages modality-consistent representations for the same biological entity, preventing noisy graph signals from dominating fusion. We evaluate under a leakage-controlled TCHard RN protocol with pair-disjoint splits, training-only model selection, and exclusion of negative-sampling metadata that otherwise trivially inflates AUROC. In this setting the task is near chance for all methods, and we do not claim state-of-the-art accuracy; our contribution is the failure-mode analysis, the alignment stabilizer, and the audited protocol itself. Among matched baselines TRACE attains the best mean AUROC (0.578±0.033 over five folds), and an ablation shows that intra-entity alignment acts as a stabilizer: it gives a small but consistent full-data gain (better on 4 of 5 folds), stays robust under substantial graph-edge corruption, and prevents collapse toward chance under limited supervision (+0.05 AUROC at 10%-20% of labels), the regime where unconstrained fusion fails. How modalities are integrated, and how carefully they are evaluated, matters more than how many are used. AVAILABILITY AND IMPLEMENTATION: Code is available at https://github.com/MineSelf2016/TRACE and archived at https://doi.org/10.5281/zenodo.20635593. Data are available at https://doi.org/10.6084/m9.figshare.31991007.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.